News Release

Nightstar Files Registration Statement For Proposed Initial Public Offering

August 31, 2017

LEXINGTON and LONDON – August 31, 2017 – Nightstar Therapeutics Limited (“Nightstar” or the “Company”), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed initial public offering in the United States of its American Depositary Shares (“ADSs”) representing ordinary shares. All ADSs to be sold in the offering will be offered by Nightstar. The number of ADSs to be sold and the price range for the proposed offering have not yet been determined. Nightstar has applied to list its ADSs on the NASDAQ Global Market under the ticker symbol “NITE”.

Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. Wedbush Securities Inc. and Chardan Capital Markets are acting as comanagers.

The securities referred to in this release are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808- 7525 ext. 6132, or by email at; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at (800) 414-3627, or by email at

A registration statement relating to and describing the terms of the offering has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness.



Alicia Davis, THRUST IR